跳转至内容
Merck
CN
  • Mechanisms of acetaminophen-induced cell death in primary human hepatocytes.

Mechanisms of acetaminophen-induced cell death in primary human hepatocytes.

Toxicology and applied pharmacology (2014-06-07)
Yuchao Xie, Mitchell R McGill, Kenneth Dorko, Sean C Kumer, Timothy M Schmitt, Jameson Forster, Hartmut Jaeschke
摘要

Acetaminophen (APAP) overdose is the most prevalent cause of drug-induced liver injury in western countries. Numerous studies have been conducted to investigate the mechanisms of injury after APAP overdose in various animal models; however, the importance of these mechanisms for humans remains unclear. Here we investigated APAP hepatotoxicity using freshly isolated primary human hepatocytes (PHH) from either donor livers or liver resections. PHH were exposed to 5mM, 10mM or 20mM APAP over a period of 48 h and multiple parameters were assessed. APAP dose-dependently induced significant hepatocyte necrosis starting from 24h, which correlated with the clinical onset of human liver injury after APAP overdose. Interestingly, cellular glutathione was depleted rapidly during the first 3h. APAP also resulted in early formation of APAP-protein adducts (measured in whole cell lysate and in mitochondria) and mitochondrial dysfunction, indicated by the loss of mitochondrial membrane potential after 12h. Furthermore, APAP time-dependently triggered c-Jun N-terminal kinase (JNK) activation in the cytosol and translocation of phospho-JNK to the mitochondria. Both co-treatment and post-treatment (3h) with the JNK inhibitor SP600125 reduced JNK activation and significantly attenuated cell death at 24h and 48h after APAP. The clinical antidote N-acetylcysteine offered almost complete protection even if administered 6h after APAP and a partial protection when given at 15 h. These data highlight important mechanistic events in APAP toxicity in PHH and indicate a critical role of JNK in the progression of injury after APAP in humans. The JNK pathway may represent a therapeutic target in the clinic.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
HEPES, ≥99.5% (titration)
Sigma-Aldrich
HEPES, BioPerformance Certified, ≥99.5% (titration), suitable for cell culture
Sigma-Aldrich
L-谷氨酰胺, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
碘化丙啶, ≥94.0% (HPLC)
Supelco
对乙酰氨基酚, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-谷氨酰胺, ReagentPlus®, ≥99% (HPLC)
SAFC
L-谷氨酰胺
Sigma-Aldrich
HEPES缓冲溶液, 1 M in H2O
USP
对乙酰氨基酚, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
HEPES, BioUltra, Molecular Biology, ≥99.5% (T)
Sigma-Aldrich
碘化丙啶 溶液
Sigma-Aldrich
对乙酰氨基酚, BioXtra, ≥99.0%
Sigma-Aldrich
对乙酰氨基酚, meets USP testing specifications, 98.0-102.0%, powder
Sigma-Aldrich
酚红, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
酚红, ACS reagent
Sigma-Aldrich
对乙酰氨基酚, analytical standard
Sigma-Aldrich
L-谷氨酰胺, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
HEPES, BioXtra, suitable for mouse embryo cell culture, ≥99.5% (titration)
Sigma-Aldrich
HEPES, BioXtra, pH 5.0-6.5 (1 M in H2O), ≥99.5% (titration)
Sigma-Aldrich
碘化丙啶, ≥94% (HPLC)
扑热息痛, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L-谷氨酰胺, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
L-谷氨酰胺
Supelco
醋氨酚 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
HEPES, anhydrous, free-flowing, Redi-Dri, ≥99.5%
Supelco
L-谷氨酰胺, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
JNK抑制剂II, JNK Inhibitor II. SP600125, CAS 129-56-6, is a potent, cell-permeable, selective, and ATP competitive inhibitor of c-Jun N-terminal kinase (JNK; IC50 = 40 nM for JNK-1 & JNK-2 & 90 nM for JNK-3).
Supelco
HEPES, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
L-谷氨酰胺, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
HEPES, Vetec, reagent grade, 99.5%